Alcon AG
SIX:ALC

Watchlist Manager
Alcon AG Logo
Alcon AG
SIX:ALC
Watchlist
Price: 76.68 CHF 1.03% Market Closed
Market Cap: 38.1B CHF
Have any thoughts about
Alcon AG?
Write Note

Alcon AG
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alcon AG
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Alcon AG
SIX:ALC
Research & Development
-$828m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Coltene Holding AG
SIX:CLTN
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medartis Holding AG
SIX:MED
Research & Development
-CHf34.6m
CAGR 3-Years
-22%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Ypsomed Holding AG
SIX:YPSN
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IVF Hartmann Holding AG
SIX:VBSN
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alcon AG
Glance View

Market Cap
37.9B CHF
Industry
Health Care

Alcon AG, a leader in the global eye care industry, is dedicated to enhancing the quality of life for patients through innovative solutions and cutting-edge technologies. Formed in 1945, the company specializes in developing, manufacturing, and marketing surgical and vision care products that cater to a wide range of eye-related conditions. With a robust portfolio that includes advanced cataract surgery instruments, contact lenses, and dry eye treatments, Alcon has positioned itself as a formidable player in both the surgical and non-surgical segments of the market. The company's commitment to research and development ensures a steady stream of innovations, attracting a loyal customer base among healthcare professionals and patients alike. For investors, Alcon AG presents a compelling opportunity driven by its strong market presence and a favorable demographic backdrop, with an aging population increasingly in need of vision care solutions. The company has demonstrated consistent revenue growth and profitability, buoyed by strategic acquisitions and a willingness to invest in future growth areas, such as digital health and myopia management. Additionally, with a robust pipeline of products and a focus on expanding markets, Alcon is well-positioned to capitalize on the growing demand for eye care solutions. As it continues to navigate the evolving landscape of the healthcare sector, Alcon AG stands out as a promising investment for those seeking exposure to the eye care market.

ALC Intrinsic Value
73.08 CHF
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Alcon AG's Research & Development?
Research & Development
-828m USD

Based on the financial report for Dec 31, 2023, Alcon AG's Research & Development amounts to -828m USD.

What is Alcon AG's Research & Development growth rate?
Research & Development CAGR 5Y
-8%

Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for Alcon AG have been -10% over the past three years , -8% over the past five years .

Back to Top